Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*.
about
Magnesium sulphate for women at term for neuroprotection of the fetusDifferent magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birthMagnesium sulphate for women at term for neuroprotection of the fetusDifferent magnesium sulphate regimens for neuroprotection of the fetus for women at risk of preterm birthEffects and Safety of Magnesium Sulfate on Neuroprotection: A Meta-analysis Based on PRISMA GuidelinesPerinatal neuroprotection updateMaternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic reviewRecent advances in the prevention and management of preterm birthMultifunctional drugs for head injuryBarriers and enablers to implementing antenatal magnesium sulphate for fetal neuroprotection guidelines: a study using the theoretical domains framework.Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis.Maternal Inflammation, Fetal Brain Implications and Suggested Neuroprotection: A Summary of 10 Years of Research in Animal Models.Accounting for multiple births in neonatal and perinatal trials: systematic review and case study.The use of antenatal magnesium sulfate for neuroprotection for infants born prematurelyLong-term child follow-up after large obstetric randomised controlled trials for the evaluation of perinatal interventions: a systematic review of the literature.High dose magnesium sulfate exposure induces apoptotic cell death in the developing neonatal mouse brain.Comparison in outcomes at two-years of age of very preterm infants born in 2000, 2005 and 2010Magnesium sulphate for fetal neuroprotection: a cost-effectiveness analysisMagnesium: potential roles in neurovascular diseaseEffect of magnesium sulfate administration for neuroprotection on latency in women with preterm premature rupture of membranes.Use and attitudes of obstetricians toward 3 high-risk interventions in MFMU Network hospitalsImplementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infantsAntenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis.Antenatal Magnesium Sulfate, Necrotizing Enterocolitis, and Death among Neonates < 28 Weeks GestationMagnesium treatment for neuroprotection in ischemic diseases of the brain.Perinatal neuroprotection.Magnesium decreases inflammatory cytokine production: a novel innate immunomodulatory mechanism.Effect of dexamethasone administered with magnesium sulfate on inflammation-mediated degradation of the blood-brain barrier using an in vitro model.Association of cord blood magnesium concentration and neonatal resuscitation.Magnesium sulfate: past, present, and future.Understanding spontaneous preterm birth: from underlying mechanisms to predictive and preventive interventions.The use of intravenous magnesium in non-preeclamptic pregnant women: fetal/neonatal neuroprotection.Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain.Magnesium sulfate increases intracellular magnesium reducing inflammatory cytokine release in neonates.Hypertension and pregnancy: expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology.Antenatal Exposure to Magnesium Sulfate Is Associated with Reduced Cerebellar Hemorrhage in Preterm NewbornsAntenatal magnesium sulphate administration for fetal neuroprotection: a French national surveyAssessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis.Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial.Optimization of Maternal Magnesium Sulfate Administration for Fetal Neuroprotection: Application of a Prospectively Constructed Pharmacokinetic Model to the BEAM Cohort.
P2860
Q24200779-52F8B7D6-CDB7-4191-9C90-326E2320EFA5Q24203697-F9AC10F8-C4DA-400E-B515-B620CA33E03EQ24234006-8FD1AA95-9A20-4D83-AE50-E256B3422A08Q24234738-6FBB1BCF-4BA1-4D3C-A621-AB732F6B164CQ26770435-A23833CC-F0ED-40D1-9FFD-EB0314B2DE1AQ26970812-BD401803-3E18-4D95-B0F8-6F4AFE4CB523Q27008489-7310001C-0FFD-472D-8AAA-A12C44A26A74Q28087299-E7D2355F-5CB3-43E8-AD5C-019C87F11A40Q30371428-A00C0118-3795-484F-B936-AE9356F587BEQ30661559-6CD21885-283C-4EC1-8760-FFF2A17049C2Q33485156-2FBDC4BF-3917-4B34-A462-2BD1280E5B85Q33633446-6FB3023A-CF95-46D4-B1F5-C3E543422213Q33748656-1311B131-D5C3-4960-96DF-CB5567146574Q34389735-83B757C0-1B67-420F-8866-95984F324EB2Q34451216-B6948C98-5114-41AC-B1C2-FECEA73F5C74Q34928666-2A6CA9EE-A825-4209-AE48-EB8ED9788531Q35058754-8A01FAA8-DCCB-4252-827C-743FBC5B0B30Q35071318-D2DC2D8C-7815-491D-B763-5E29D4922A54Q35159997-A7E8BBCA-DF6B-4820-A010-E56F2E5B92A2Q35204549-A0EFAC55-3260-4204-AFAA-E61A43E795A5Q36016724-DBDE642D-E38E-4E02-8E1F-C584F3603B6CQ36102790-60C53A36-785C-40BF-B227-520FBA915F52Q36283990-DAAD713E-C48B-45DB-A0BD-06CB3045BDC6Q36753526-0E0FC04F-607F-4F06-B494-F6AC81AC89F0Q36811695-2779414E-2F3F-439B-8006-94BA9C5C2C99Q37444015-2E09BE79-5111-45B0-ADB0-19820F20A15CQ37448003-CECA4552-3CA8-4CE0-A071-B649B3F55658Q37651320-76B4891A-F4D2-4FC5-9273-793673AF730DQ37721256-90246561-EE82-40A7-A1F9-3A345E881ECAQ37953517-E3849F5B-E8E1-458B-B398-5BD5F9D78B3CQ38089568-2088F120-092C-4582-A314-645FAF21B97CQ38287116-92554C50-66B9-4027-9281-BA5CE8F91601Q38626004-22819C7B-8799-411E-AC23-345711F51C4BQ39165493-EA85F7D2-1291-4BCF-B1D0-D55CA3A8A5E2Q39175116-345DB9DC-A5F9-4089-90E4-1AEE525A27D3Q40480909-E0438A26-ECD2-4767-8A54-A534208FBE07Q41153841-33333724-2B3F-428A-9DA8-B1CEE8286AB4Q42370183-CBF05C3F-DA8F-4581-ACAE-074599ED22FEQ46008896-463B2138-64FF-4FE3-B19B-EC432117D4F8Q47288097-41B6D0DF-312F-40C3-9D90-21970E11B262
P2860
Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial*.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@en
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@nl
type
label
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@en
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@nl
prefLabel
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@en
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@nl
P2093
P921
P1476
Magnesium sulphate given befor ...... ised controlled PREMAG trial*.
@en
P2093
J Bénichou
M-F Hellot
PREMAG trial group
V Zupan-Simunek
P304
P356
10.1111/J.1471-0528.2006.01162.X
P577
2006-12-04T00:00:00Z